These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23633496)

  • 1. Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy.
    Brautbar A; Barbalic M; Chen F; Belmont J; Virani SS; Scherer S; Hegele RA; Ballantyne CM
    J Lipid Res; 2013 Jul; 54(7):1980-7. PubMed ID: 23633496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
    Brautbar A; Covarrubias D; Belmont J; Lara-Garduno F; Virani SS; Jones PH; Leal SM; Ballantyne CM
    Atherosclerosis; 2011 Dec; 219(2):737-42. PubMed ID: 21889769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia.
    Gao F; Ballantyne C; Ma L; Virani SS; Keinan A; Brautbar A
    Atherosclerosis; 2014 Jun; 234(2):249-53. PubMed ID: 24704626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
    Roth EM; Rosenson RS; Jones PH; Davidson MH; Kelly MT; Setze CM; Lele A; Thakker K
    J Clin Lipidol; 2012; 6(6):534-44. PubMed ID: 23312049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
    Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
    Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
    Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
    Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
    Davidson M; Rosenson RS; Maki KC; Nicholls SJ; Ballantyne CM; Setze C; Carlson DM; Stolzenbach J
    Cardiovasc Drugs Ther; 2012 Aug; 26(4):349-58. PubMed ID: 22622962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.
    Rosenson RS; Carlson DM; Kelly MT; Setze CM; Hirshberg B; Stolzenbach JC; Williams LA
    Cardiovasc Drugs Ther; 2011 Feb; 25(1):47-57. PubMed ID: 21174145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.
    Ma L; Ballantyne CM; Belmont JW; Keinan A; Brautbar A
    J Lipid Res; 2012 Nov; 53(11):2425-8. PubMed ID: 22896670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triglyceride-raising APOA5 genetic variants are associated with obesity and non-HDL-C in Chinese children and adolescents.
    Zhu WF; Wang CL; Liang L; Shen Z; Fu JF; Liu PN; Lv LQ; Zhu YM
    Lipids Health Dis; 2014 Jun; 13():93. PubMed ID: 24903888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.
    Roth EM; Rosenson RS; Carlson DM; Fukumoto SM; Setze CM; Blasetto JW; Khurmi NS; Stolzenbach JC; Williams LA
    Cardiovasc Drugs Ther; 2010 Dec; 24(5-6):421-8. PubMed ID: 20953684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.
    Lai CQ; Arnett DK; Corella D; Straka RJ; Tsai MY; Peacock JM; Adiconis X; Parnell LD; Hixson JE; Province MA; Ordovas JM
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1417-25. PubMed ID: 17431185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
    Brautbar A; Virani SS; Belmont J; Nambi V; Jones PH; Ballantyne CM
    J Lipid Res; 2012 Mar; 53(3):556-560. PubMed ID: 22236405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Lipid Response to Statins Is Associated With Variants in the BUD13-APOA5 Gene Region.
    OʼBrien SE; Schrodi SJ; Ye Z; Brilliant MH; Virani SS; Brautbar A
    J Cardiovasc Pharmacol; 2015 Aug; 66(2):183-8. PubMed ID: 25900265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status.
    Feitosa MF; An P; Ordovas JM; Ketkar S; Hopkins PN; Straka RJ; Arnett DK; Borecki IB
    Atherosclerosis; 2011 Apr; 215(2):435-9. PubMed ID: 21324458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). cmb@bcm.tmc.edu.
    Ballantyne CM; Davidson MH; Setze CM; Kelly MT
    J Clin Lipidol; 2011; 5(5):401-7. PubMed ID: 21981842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis.
    Laurila PP; Naukkarinen J; Kristiansson K; Ripatti S; Kauttu T; Silander K; Salomaa V; Perola M; Karhunen PJ; Barter PJ; Ehnholm C; Peltonen L
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):346-52. PubMed ID: 19910639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic effects of genetic variants of APOA5 and BTN2A1 on dyslipidemia or metabolic syndrome.
    Hiramatsu M; Oguri M; Kato K; Horibe H; Fujimaki T; Watanabe S; Satoh K; Aoyagi Y; Tanaka M; Shin DJ; Lee JH; Jang Y; Yamada Y
    Int J Mol Med; 2012 Jul; 30(1):185-92. PubMed ID: 22576629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
    Jones PH; Bays HE; Davidson MH; Kelly MT; Buttler SM; Setze CM; Sleep DJ; Stolzenbach JC
    Clin Drug Investig; 2008; 28(10):625-34. PubMed ID: 18783301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.